FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices
Lawsuit Does Not Cite Overlap In Companies’ Portfolios
The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.
